Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.47 |
| ▸ | F11 | P03951 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14142082 | 0.92 | GPR119 (0.49) | GPR119F11DDB1CRBNTLR7 | |
| SCHEMBL10179766 | 0.90 | GPR119 (0.49) | GPR119F11DDB1CRBNTLR7 | |
| SCHEMBL10179392 | 0.90 | GPR119 (0.39) | GPR119F11TLR7 | |
| SCHEMBL10179177 | 0.89 | EGLN1 (0.34) | GPR119F11 | |
| SCHEMBL10179397 | 0.86 | TRPV3 (0.42) | GPR119DDB1CRBNTLR7TRPV3 | |
| SCHEMBL14142049 | 0.85 | GPR119 (0.49) | GPR119F11TRPV3 | |
| SCHEMBL10179775 | 0.83 | TLR7 (0.39) | GPR119DDB1CRBNTLR7TRPV3 | |
| SCHEMBL14142236 | 0.81 | GPR119 (0.40) | GPR119F11TLR7 | |
| SCHEMBL14141945 | 0.80 | ALDH1A1 (0.36) | GPR119F11 | |
| SCHEMBL12544773 | 0.79 | GPR119 (0.39) | GPR119TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | GPR119 1/4885F11 1489/4885DDB1 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.